EUCTR2016-004154-15-IT进行中（未招募）1 期
A phase II, multicentric, open label, non-randomized, interventional study of Pembrolizumab in combination with Electrochemotherapy in patients with unresectable melanoma with superficial or superficial and visceral metastases - ECT_PEMBRO
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Have a histologically confirmed advanced melanoma stages III b/c or IV, with at least the following superficial lesions: 5 lesions if diameter < 1 cm or 3 lesions if diameter > 1 cm.
- •2.Could have received previous therapy included CT, antiCTLA4 or antiBRAF/antiMEK treatment or be treatment naïve.
- •3.Be willing and able to provide written informed consent/assent for the trial.
- •4.Be ¿ 18 years of age on day of signing informed consent.
- •5.Have measurable disease based on RECIST 1.1.
- •6.Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.
- •7.Have a performance status = 2 on the ECOG Performance Scale. (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.)
- •8.Demonstrate adequate organ function as defined in
- •9.Have a baseline total body CT scan (brain MRI if brain metastasis are suspected)
- •a.Patients with brain metastasis are allowed to participate if previously treated and brain lesion stability or inactivity is demonstrated. Patients with a history of brain metastasis are required to have a pre-baseline brain MRI at least 60 days (2 months) before the Screening/Baseline visit (Visit 1) for comparison to the Screening (Visit 1) MRI. Patients for whom MRI is contraindicated will undergo head CT. Stable/inactive disease is determined by comparing the pre baseline and screening/baseline MRI/CT results.
- •b.Patients presenting with brain metastasis at Screening/Baseline who had no known previous brain involvement and who had no brain MRI/CT tests at least 60 days (2 months) before Screening/Baseline are considered screening failures and will be excluded from study enrollment.
- •10.Have cutaneous or subcutaneous metastases from melanoma that are accessible for the application of electric pulses using the single use, sterile CLINIPORATOR™ electrodes (5 lesions if diameter <1 cm or 3 lesions if diameter >1 cm). For patients presenting with more than 7 lesions, the lesions with the largest diameters that fall within the <10 to 30 mm size requirements will be considered target lesions for RECIST criteria and study purposes. The others will be recorded and monitored but will not considered as Target.
- •11.Have lesions clearly requiring palliative treatment [e.g., symptomatic (bleeding, draining, painful), disfiguring or causing distress to the patient].
- •12.A treatment-free period of three (3) weeks before enrolling in the study. NOTE: Patients receiving concomitant treatments for unrelated existing pathologies are eligible for enrollment.
- •13.Life expectancy > 3 months.
- •14.Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •15.Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 – Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is
排除标准
- •1.Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment or has any ongoing treatment for melanoma or with any non-study anticancer therapy or immunosuppressive agent.
- •2.Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •3.Has a known history of active TB (Bacillus Tuberculosis)
- •4.Hypersensitivity to pembrolizumab or any of its excipients or known allergies to Bleomycin.
- •5.Has received a cumulative lifetime dose of Bleomycin exceeding 250 mg/m2
- •6.Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •7.Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent.
- •8.Patient has a history of a malignancy (other than the disease under treatment in the study) within 5 years prior to first study drug administration. This should exclude adequately treated Stage 1 or Stage 2 basal/squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other in situ cancers. Shorter intervals can be considered after discussion with Merck.
- •9.Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 14 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- •10.Has epilepsy.
- •11.Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •12.Has a history of (no-infectious) pneumonitis that require steroids or current pneumonitis.
- •13.Has an active infection requiring systemic therapy.
- •14.Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •15.Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
研究者
相似试验
进行中（未招募）
不适用
A open label, phase 2, non randomized, multicentre trial to assess the feasibility of induction treatment with 5-azacitidine (5-AZA) followed by allogeneic stem cell transplantation (allo-SCT) or continued 5-AZA treatment in patients without a suitable -sibling or unrelated- stem cell donor with IPSS Int-2/High risk myelodysplastic syndromes (MDS) - BMT-AZAmyelodysplastic syndrome (MDS)MedDRA version: 9.1Level: LLTClassification code 10028533EUCTR2010-019673-15-ITniversit? Cattolica del Sacro Cuore
已完成
2 期
Clinical Study to assess the immune response and safety of Measles, Mumps and Rubella (MMR) vaccine (Live) (Freeze-dried) of M/s Cadila Healthcare Ltd. in healthy pediatric subjects aged 15-18 monthsCTRI/2014/01/004339Cadila Healthcare Ltd100
已完成
2 期
Clinical Study to assess the immune response and safety of Measles vaccine (Live) (Freeze-dried) of M/s Cadila Healthcare Ltd. in healthy pediatric subjects aged 9-12 monthsCTRI/2014/01/004343Cadila Healthcare Ltd100
Unknown
2 期
A study to evaluate the effect of immunoadjuvant therapy with Mycobacterium w and Docetaxel in Metastatic Hormone Refractory Prostate Cancer.CTRI/2007/091/000033Cadila Pharmaceuticals ltd176
进行中（未招募）
1 期
A Phase 1/2, Study to measure the safety, tolerability and the action of drugs in the body (method and rate of excretion; duration of effect on the body) and effectivity of Burosumab in children from birth to less than 1 year of age with inheritable form of ricketsXLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burnett et al. 1964), (Imel et al. 2005). XLH is the most common inherited form of rickets and the most common inherited defect in renal tubular phosphate transport. XLH is transmitted as an X-linked dominant disorder (Dixon et al. 1998).MedDRA version: 20.0Level: LLTClassification code 10016206Term: Familial hypophosphataemic ricketsSystem Organ Class: 100000004850EUCTR2019-000469-19-SEKyowa Kirin Pharmaceutical Development Ltd.20